PMID- 35647838
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220724
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 26
IP  - 10
DP  - 2022 May
TI  - A short review on cervical cancer cell lines characterization and their 
      corresponding human leukocyte antigen (HLA) type expression.
PG  - 3570-3576
LID - 28852 [pii]
LID - 10.26355/eurrev_202205_28852 [doi]
AB  - Cervical cancer is one of the leading causes of death in women worldwide. 
      Extensive research is ongoing to develop efficient diagnostics and therapeutic 
      approaches for cervical cancer, which rely on the preliminary studies based on 
      cervical cell lines. It is essential to characterize these cell lines to ensure 
      the suitability of the cells for each study. In this review, the human leukocyte 
      antigen (HLA) molecule expressed on each cervical cancer line is presented. HLA 
      characterization of the cervical cancer cell lines is essential to increase the 
      specificity of treatment towards certain type of cervical cancer, allowing 
      accurate therapy. HLA characterization is also important for the generation of 
      novel diagnostics and/or therapeutics molecules, especially for HLA-based 
      strategies.
FAU - Rajan, R S
AU  - Rajan RS
AD  - Institute for Research in Molecular Medicine (INFORMM), Universiti Sains 
      Malaysia, Penang, Malaysia. venugopal@usm.my.
FAU - Dass, S A
AU  - Dass SA
FAU - Tye, G J
AU  - Tye GJ
FAU - Balakrishnan, V
AU  - Balakrishnan V
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Cell Line, Tumor
MH  - Female
MH  - *HLA Antigens/genetics
MH  - Humans
MH  - *Uterine Cervical Neoplasms/genetics
EDAT- 2022/06/02 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/06/01 11:59
PHST- 2022/06/01 11:59 [entrez]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
AID - 28852 [pii]
AID - 10.26355/eurrev_202205_28852 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2022 May;26(10):3570-3576. doi: 
      10.26355/eurrev_202205_28852.